- BIONOTE
- Support
- News
-
High immunogenicity following WSAVA guidelines, confirmed by VcheckA paper using Vcheck CPV Ab testing has been published with results proving that regular vaccinations under the WSAVA guidelines increase the protection rate against parvovirus. - [Related document] Evaluation materials Canine parvovirosis is a systemic disease caused by CPV-2 (canine parvovirus type 2). Typical symptoms of parvovirus include lack of appetite, vomiting, and bloody diarrhea.The most effective way to prevent the parvovirus is prophylactic vaccination, and according to the WSAVA guidelines, it is recommended that booster vaccines be performed not more often than every 3 years after the initial puppy vaccination. Based on the history of the vaccination against CPV, the study population was divided into three groups: - Group I (n=59): Dogs regularly vaccinated against the disease according to WSAVA guidelines- Group II (n=77): Dogs that completed the full course of CPV immunization as puppies but have not received a booster dose in the past three years- Group III (n=64): Dogs that have not received vaccination against parvovirus in their lifetime Statistical analysis showed a significantly greater number of dogs with high titers of antibodies against CPV of HI ≥ 80 in Group I (86%) compared to Group II (73%), and Group III (72%). Table 1. Values of antibody titers in HI test for CPV in dogs in each group Gender and race were not found to have an influence over the value of antibody titers against CPV. Regular vaccinations by WSAVA recommendations increase protection against CPV, as evidenced by the lowest percentage of dogs with HI < 80 in Group I, which were regularly vaccinated at least every 3 years. Additionally, the presence of dogs with high antibody titers against CPV in Group III indicates widespread contamination of the pathogen within the environment. Bionote's immunofluorescence analyzer, Vcheck, is designed to generate fast and accurate diagnoses for in-clinic testing through its automative blood testing system that can run 24 quantitative and semi-qualitative tests (NT-proBNP, SDMA, D-dimer, CRP, SAA, cPL, fPL, cCortisol, T4, TSH, Progesterone, and Antibody titers).
- 2021.03.24
- Hits : 5,304
-
NowCheck COVID-19 Ag rapid diagnosis kit for Nasal swab, CE certification complete
Bionote developed a nasal swab test version of the COVID-19 antigen rapid diagnostic kit, in addition to the existing nasopharyngeal swab test. This new version has also obtained Certification of EU product notification as well. Antigen rapid diagnostic kit is a widely used screening and diagnosing method for infectious diseases such as influenza in hospitals. The test procedure for a rapid kit is simple, fast, and efficient, requiring only 15 to 30 minutes without the need for any additional equipment. With such efficiency, antigen tests enable more massive testing with a faster diagnosis compared to a molecular diagnostic method such as a PCR test. The NowCheck COVID-19 Ag Test, which is manufactured and sold by Bionote, is a diagnostic kit that quickly determines SARS-CoV-2 infection (COVID-19). Until now, it previously came only with nasopharyngeal swab specimens, but a new nasal swab type has recently been added. A clinical evaluation conducted in Brazil between July and August confirmed an excellent performance of 89.2% (91/102) sensitivity and 97.3% (290/298) specificity. In particular, the sensitivity was found to be up to 92.2% in patients when the days from symptom onset were ≤ 7 days. While most conventional COVID-19 antigen tests are performed by inserting a swab deep into a nostril to collect the specimen from the nasopharynx, it may cause discomfort among the patients during the collection process. That is why patients will find Bionote's newly developed nasal swab version relatively easier to use compared to the previous nasopharyngeal swab test. The nasal cavity is located outward compared to the nasopharynx, making it easier to collect the specimens with less discomfort and thus requiring less proficiency from inspectors. Since there is no effective treatment for COVID-19, a more active response to the COVID-19 pandemic should be made possible with rapid diagnostic kits. CE certified NowCheck COVID-19 test offers not only accurate results, but also more swab options for the consumers to choose from. For those who are interested in NowCheck COVID-19 Tests, please contact your local distributor or mail to [bionote@bionote.co.kr].
- 2020.11.27
- Hits : 3,750
-
BIONOTE provides diagnostic solutions for COVID-19Coronavirus disease 2019 (COVID-19) is a new disease, caused by a novel coronavirus (SARS-CoV-2) that has not previously been seen in humans. It is a respiratory illness that can spread from person to person. The rapid diagnosis of COVID-19 is critical for the prevention and control of this pandemic. Antigen and antibody tests are highly accurate, easy to perform, and require minimal education for users. As a reference standard method, RT-PCR has been performed to make a definitive diagnosis of COVID-19 infection. However, even PCR may result in high false negative results and requires long turn-around-time. Antigen testing can be a "breakthrough" innovation to help screen more people for viruses. It detects the presence of viral proteins, which enables the identification of acute or early infection. Antibody status can be used to aid the clinical diagnosis of suspected cases that present 7 days or more after the start of symptoms. IgM is an early phase immunoglobulin that will develop first during acute infection. IgG is largely responsible for long-term immunity after infection. All patients will develop IgM and IgG by day 14. ü NowCheck COVID-19 Ag Test is a rapid chromatographic immunoassay for the qualitative detection of specific SARS-CoV-2 antigens present in the human nasopharynx. - In a retrospective, multi-center, randomized, and single-blinded study, the NowCheck COVID-19 Ag Test showed 88.68% sensitivity (47/53) and 98.25% specificity (112/114) compared to PCR assays. - No cross-reaction with potential cross-reactive substances except SARS-coronavirus. - No interference with Endogenous/Exogenous interfering substances such as anti-viral drugs, antibiotics, or anti-inflammatory medications. ü NowCheck COVID-19 IgM/IgG Test is a rapid chromatographic immunoassay for the qualitative detection of specific antibodies to SARS-CoV-2 present in human serum, plasma, or whole blood. - In a retrospective, multi-center, randomized, and single-blinded study, the NowCheck COVID-19 IgM/IgG Test showed 96.77% sensitivity (30/31) and 98.65% specificity (73/74), compared to PCR assays. - Additional quality control for NowCheck COVID-19 Ag and IgM/IgG Tests are available to be purchased as optional contents. For those who are interested in NowCheck COVID-19 Tests, please contact your local distributor or mail to [bionote@bionote.co.kr].
- 2020.06.08
- Hits : 5,411